Prescient Therapeutics appoints leading brain cancer specialist to advisory board
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to...
Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps...
Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple...
Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline...
Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected...
Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant...
Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute...
Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to...
This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.